Torisel (temsirolimus)
- Region
- 🇪🇺 EU
- Active substance
- temsirolimus
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Carcinoma, Renal Cell; Lymphoma, Mantle-Cell
- CHMP opinion
- Thu 20 Sep 2007
- EU approval
- Mon 19 Nov 2007
- Application
- EMEA/H/C/000799
- ATC
- L01XE09
- Official record
- www.ema.europa.eu
Indication
Renal-cell carcinoma Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors. Mantle-cell lymphoma Torisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).
Regulatory milestones
No milestones recorded in the last year.
Follow Torisel
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.